Outset Medical, Inc.
Outset Medical, Inc. (OM) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Outset Medical, Inc. (OM), featuring income statements, balance sheets, and cash flow data.
Outset Medical, Inc. (OM) Income Statement & Financial Overview
Review Outset Medical, Inc. OM income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $29.75M | $29.47M | $28.67M | $27.39M |
| Cost of Revenue | $18.69M | $18.72M | $18.85M | $17.61M |
| Gross Profit | $11.07M | $10.75M | $9.82M | $9.78M |
| Gross Profit Ratio | $0.37 | $0.36 | $0.34 | $0.36 |
| R&D Expenses | $5.51M | $7.89M | $8.14M | $9.73M |
| SG&A Expenses | $21.95M | $24.72M | $25.52M | $30.81M |
| Operating Expenses | $27.46M | $32.61M | $33.66M | $40.55M |
| Total Costs & Expenses | $46.15M | $51.33M | $52.51M | $58.15M |
| Interest Income | $1.98M | $2.04M | $2.15M | $2.47M |
| Interest Expense | $3.56M | $5.83M | $6.07M | $6.01M |
| Depreciation & Amortization | $1.29M | $1.41M | $2.15M | $1.47M |
| EBITDA | -$20.81M | -$18.41M | -$21.69M | -$26.82M |
| EBITDA Ratio | -$0.70 | -$0.62 | -$0.76 | -$0.98 |
| Operating Income | -$16.40M | -$21.86M | -$23.84M | -$30.76M |
| Operating Income Ratio | -$0.55 | -$0.74 | -$0.83 | -$1.12 |
| Other Income/Expenses (Net) | -$9.27M | -$3.78M | -$3.92M | -$3.54M |
| Income Before Tax | -$25.67M | -$25.64M | -$27.76M | -$34.30M |
| Income Before Tax Ratio | -$0.86 | -$0.87 | -$0.97 | -$1.25 |
| Income Tax Expense | $115000.00 | -$4000.00 | $182000.00 | $151000.00 |
| Net Income | -$25.78M | -$25.64M | -$27.94M | -$34.45M |
| Net Income Ratio | -$0.87 | -$0.87 | -$0.97 | -$1.26 |
| EPS | -$7.44 | -$0.50 | -$0.55 | -$0.66 |
| Diluted EPS | -$7.44 | -$0.50 | -$0.55 | -$0.66 |
| Weighted Avg Shares Outstanding | $3.46M | $3.42M | $3.37M | $3.46M |
| Weighted Avg Shares Outstanding (Diluted) | $3.46M | $3.42M | $3.37M | $3.46M |
Financial performance has remained strong, with revenue growing from $27.39M in Q2 2024 to $29.75M in Q1 2025. Gross profit continued to perform well, with margins at 37% in the latest quarter. Operating income reached -$16.40M in Q1 2025, holding a steady -55% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$20.81M. Net income dropped to -$25.78M, keeping EPS at -$7.44. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan